Exact Sciences (NASDAQ:EXAS) EVP Brian Baranick Sells 2,858 Shares of Stock

Exact Sciences Corporation (NASDAQ:EXAS) EVP Brian Baranick sold 2,858 shares of the company’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total transaction of $200,288.64. Following the transaction, the executive vice president directly owned 22,368 shares of the company’s stock, valued at $1,567,549.44. This represents a 11.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Exact Sciences Stock Down 3.5%

EXAS stock opened at $67.22 on Friday. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $72.81. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. The company has a market cap of $12.73 billion, a PE ratio of -12.38, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34. The business’s 50-day simple moving average is $57.71 and its 200 day simple moving average is $53.24.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The company’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.21) EPS. Exact Sciences has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Exact Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of EXAS. Vanguard Group Inc. raised its holdings in shares of Exact Sciences by 3.6% in the first quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company’s stock valued at $763,535,000 after buying an additional 617,384 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Exact Sciences by 11.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company’s stock worth $277,225,000 after purchasing an additional 643,631 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Exact Sciences by 31.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock valued at $213,889,000 after purchasing an additional 939,888 shares in the last quarter. Mackenzie Financial Corp raised its position in Exact Sciences by 12.4% in the 1st quarter. Mackenzie Financial Corp now owns 3,281,639 shares of the medical research company’s stock worth $142,062,000 after purchasing an additional 362,314 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Exact Sciences by 120.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock worth $135,453,000 after buying an additional 1,707,287 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EXAS. TD Cowen increased their price objective on shares of Exact Sciences from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank Of Canada dropped their price target on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating for the company in a research report on Thursday, August 7th. Zacks Research raised Exact Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exact Sciences in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus raised their target price on Exact Sciences from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $73.44.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.